Mounjaro 15 MG/0.5 ML 4 vial or pen

Description

Mounjaro 15 MG/0.5 ML 4 vial or pen

What is Mounjaro?
Mounjaro (tirzepatide) injection is used to lower blood sugar (blood glucose) and A1C levels in adults with type 2 diabetes. Mounjaro is a once-weekly injection that should be used along with diet and exercise. Clinical studies of 15 mg of Munjaro (tirzepatide) for weight loss showed that patients lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% for placebo. Zepbound is the brand name for the weight-loss version of Mounjaro. They both contain the same active ingredient (tirzepatide). Mounjaro is FDA-approved for type 2 diabetes and Zepbound is FDA-approved to help with weight loss.

Mounjaro is the first GIP and GLP-1 receptor agonist that works on glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors.

Mounjaro works to lower blood sugar by helping the pancreas produce more insulin, reducing the amount of sugar the liver makes, and slowing the rate at which food passes through the body, making you feel full. It does this by activating two receptors, GIP and GLP-1, which are natural incretin hormones that help regulate blood sugar levels.

Mounjaro injection became an FDA-approved drug on May 13, 2022, to improve blood sugar (glucose) levels in adults with type 2 diabetes when used together with diet and exercise. Mounjaro is not for people with type 1 diabetes. It is not known whether this drug can be used in people with pancreatitis.

Is Mounjaro FDA-approved for weight loss?
Yes, the active ingredient in Mounjaro, tirzepatide, is approved for weight loss, but it is under the brand name Zepbound. Zepbound has the same active ingredient as Mounjaro, and both are made by Eli Lilly and Company.

The brand name Mounjaro is not FDA-approved for weight loss. Mounjaro is an FDA-approved medication used to improve blood sugar (glucose) levels in adults with type 2 diabetes mellitus when used together with diet and exercise.

The active ingredient in Mounjaro, tirzepatide, was used in the Phase 3 SURMOUNT-1 72-week weight loss clinical trial. The mean weight loss for tirzepatide was 15% for the 5 mg dose, 19.5% for the 10 mg dose, 20.9% for the 15 mg dose, and 3.1% for placebo. The study included patients who were overweight, obese, and had weight-related health problems, but excluded patients with diabetes.

How much does Mounjaro cost?
Ask your pharmacist, or visit the website

What are the side effects of Mounjaro?

Common side effects of Mounjaro
The most common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain, affecting 5% or more of patients.

Serious side effects of Mounjaro
Stop using this medicine and get emergency medical help if you have:

Signs of an allergic reaction: hives; difficulty breathing; feeling light-headed; swelling of your face, lips, tongue, or throat; or
Pancreatitis with symptoms of severe pain in your upper abdomen that spreads to your back, nausea, and vomiting.
Call your doctor if you have:

Severe stomach problems;

Eye side effects or vision changes, including blurred or dim vision;
Symptoms of a thyroid tumor may include swelling or a lump in the neck, difficulty swallowing, a hoarse voice, or if you feel short of breath;
Gallbladder problems with symptoms including chalky stools, stomach pain after eating, nausea, heartburn, bloating, and severe pain in the upper abdomen that may spread to your back;
Symptoms of low blood sugar may include headache, hunger, weakness, sweating, confusion, irritability, dizziness, fast heartbeat, or feeling anxious; or
Kidney problems with little or no urination, swelling in the feet or ankles, feeling tired, or shortness of breath.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You can report side effects to the FDA at 1-800-FDA-1088.

Warning
Seek immediate medical attention if you have symptoms of a thyroid tumor, such as a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath.

In studies in rats, tirzepatide and drugs that work similarly have caused thyroid tumors, including thyroid cancer. It is not known whether Munjaro will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC).

You should not use this medicine if you have or have a family history of thyroid cancer.